STOCK TITAN

US Nuclear (UCLE) 10-Q Filings

UCLE OTC

Here are the 10-Q quarterly reports from US Nuclear Corp (UCLE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow UCLE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UCLE filings page.

Rhea-AI Summary

US Nuclear Corp. reported first-quarter 2026 sales of $352,209, down 26.1% year over year, and a net loss of $187,086, compared with a $560,232 net loss a year earlier. Gross profit fell to $154,995 from $348,917, and gross margin was 44.01%, compared with 73.19%. Overhoff sales declined $135,369, partly offset by a $10,873 increase in Optron sales.

At March 31, 2026, cash was $67,318, current assets were $1,194,749 and current liabilities were $2,186,126; shareholders’ deficit was $740,071. Operating activities used $126,563 in cash. The company said its quarterly loss and $21,424,243 accumulated deficit raise substantial doubt about its ability to continue as a going concern.

Management anticipates needing approximately $5,000,000 in additional capital over the next 12 months. Disclosure controls and procedures were not effective as of March 31, 2026. On July 1, 2026, the company received notices of default on two U.S. Bank demand line-of-credit notes; principal and interest became due June 30, and the default rate is 5% per annum plus the otherwise payable rate.

Rhea-AI Summary

US Nuclear Corp. reported Q3 2025 sales of $595,305, slightly below the prior year, but moved to net income of $147,355 versus a loss a year earlier. The quarter benefited from $475,000 of other income from terminating cooperative agreements with fusion-technology partners MIFTI and MIFTEC. For the first nine months, sales were $1,519,081, down about 13%, and the company recorded a net loss of $620,676.

At September 30, 2025, cash was $75,907 and total assets were $2,537,709, against total liabilities of $2,391,319. Shareholders’ equity improved to $146,390 from a deficit at year-end 2024, helped by share and preferred stock issuances, warrant-related capital, and debt conversions, including several related-party notes. The filing states that recurring losses and an accumulated deficit of $20,466,094 raise “substantial doubt” about the company’s ability to continue as a going concern, and management plans to seek about $5,000,000 in additional capital over the next twelve months.